On January 6, 2023, lecanemab (trade name Leqembi), an Alzheimer's disease drug developed by Eisai and Biogen, received conditional approval from the FDA. The results of its Phase 3 clinical trial showed that the drug slowed cognitive decline in Alzheimer's disease patients by 27%. The FDA has conducted a further review of the clinical trial results to determine whether the drug can be fully approved. Read More
